The MSX2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal knockout cell population. This product consists of a heterogeneous pool of Raji B lymphocytes carrying diverse loss-of-function mutations in the MSX2 gene, generated by transient transfection of Cas9 and guide RNA targeting MSX2 coding sequences. The polyclonal format enables rapid functional screening without clonal isolation, capturing a range of knockout efficiencies and mutational spectra across the cell population. Unlike monoclonal cell lines, this polyclonal pool can reveal dominant phenotypes and off-target effects in a more physiologically relevant manner. The product is provided as a ready-to-use suspension culture, suitable for downstream experimental workflows such as proliferation assays and transcriptomic analyses.
Raji cells, derived from a patient with Burkitt lymphoma, are an Epstein-Barr virus (EBV)-positive, suspension lymphoblastoid cell line widely used as a model for B cell lymphoma and immune signaling. These malignant B lymphocytes exhibit constitutive NF-??B activity and express surface markers characteristic of mature B cells. They are particularly valuable for studying B cell receptor signaling, apoptosis regulation, and the interplay between viral latency and host gene expression. The EBV-positive background adds an additional layer of complexity, as viral oncoproteins like LMP1 modulate signaling pathways that intersect with MSX2 functions. This cell line supports a broad range of biochemical and genetic assays, making it an ideal chassis for dissecting transcription factor networks.
MSX2 encodes a homeodomain transcriptional repressor that modulates development and homeostasis by inhibiting target gene transcription. It functions downstream of bone morphogenetic protein (BMP) receptors and SMAD1/5/8 phosphorylation, which in turn activate MSX2 expression. Key upstream regulators also include WNT ligands, TGF-??, and FGF, linking MSX2 to multiple morphogen pathways. MSX2 directly represses promoters of genes such as CDKN1A (p21), CCND1 (cyclin D1), and RUNX2, while interacting with transcription factors DLX5, DLX6, PAX3, and the co-repressor TBP. In the context of BMP signaling, MSX2 forms complexes with SMAD1 and competes with other transcriptional activators, thereby fine-tuning proliferation and differentiation programs.
In B cell lymphoma, MSX2 likely influences proliferation, apoptosis, and NF-??B signaling, though its precise roles remain poorly defined. The Raji polyclonal knockout model enables researchers to assess the impact of MSX2 loss on cell cycle progression, survival, and oncogenic signaling. Given the interactions with BMP and WNT pathways, which are often dysregulated in lymphoma, this system allows investigation of cross-talk between developmental signals and malignant transformation. The polyclonal nature may unmask compensatory mechanisms and heterogeneity in response to MSX2 disruption, offering a powerful platform for drug target validation and pathway dissection.
Typical applications include functional genomics studies in B cell malignancy, where MSX2 knockout cells can be subjected to proliferation and apoptosis assays to evaluate its role in cell growth. Transcriptome analysis via RNA-seq reveals downstream target networks, while ChIP-qPCR confirms MSX2 binding at promoters of genes like CDKN1A and BGLAP. Western blotting and RT-qPCR verify protein and mRNA levels, respectively. Flow cytometry profiles cell cycle alterations, and co-culture experiments explore interactions with the tumor microenvironment. This polyclonal knockout product serves as a versatile loss-of-function tool for cancer biologists, immunologists, and drug developers. For further technical details, please contact Ascent Research.
